Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.19 (market cap $6.57B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 4.4× uniQure N.V. Ordinary Shares's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IOVA | QURE | |
|---|---|---|
Market Cap | $6.57B | $1.48B |
Volume | 11,838,721 | 2,488,780 |
Sector | Health | Health |
52-Week High | $14.82 | $70.59 |
52-Week Low | $1.81 | $9.03 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
